Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.33 |
| ▸ | CD38 | P28907 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394197 | 0.87 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL6808774 | 0.78 | KMT2A (0.41) | L3MBTL1KMT2AALDH1A1QPCT | |
| SCHEMBL21039172 | 0.76 | ALDH1A1 (0.36) | L3MBTL1TBXAS1ALDH1A1 | |
| SCHEMBL18631522 | 0.75 | L3MBTL1 (0.38) | L3MBTL1CYP24A1 | |
| SCHEMBL4140655 | 0.75 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1 | |
| SCHEMBL17285650 | 0.75 | ALDH1A1 (0.35) | L3MBTL1TBXAS1ALDH1A1QPCT | |
| SCHEMBL5257422 | 0.75 | QPCT (0.45) | L3MBTL1MEN1KMT2AALDH1A1QPCT | |
| SCHEMBL6735760 | 0.74 | ALDH1A1 (0.43) | L3MBTL1TBXAS1ALDH1A1 | |
| SCHEMBL4256422 | 0.74 | QPCT (0.39) | CYP24A1TBXAS1ALDH1A1QPCT | |
| SCHEMBL21039055 | 0.73 | EGLN3 (0.36) | L3MBTL1TBXAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2331544-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | Pfizer Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010018481-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | L3MBTL1 3242/4885CYP24A1 4470/4885TBXAS1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.